371 related articles for article (PubMed ID: 38519953)
1. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
[TBL] [Abstract][Full Text] [Related]
2. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
Tong JTW; Harris PWR; Brimble MA; Kavianinia I
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391
[TBL] [Abstract][Full Text] [Related]
3. Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
Fu Z; Li S; Han S; Shi C; Zhang Y
Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
5. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
Chia CSB
ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
[TBL] [Abstract][Full Text] [Related]
7. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
8. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.
Wu Q; Qian W; Sun X; Jiang S
J Hematol Oncol; 2022 Oct; 15(1):143. PubMed ID: 36209184
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
14. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
15. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
Reuss JE; Gosa L; Liu SV
Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
[TBL] [Abstract][Full Text] [Related]
16. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
17. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
18. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
[TBL] [Abstract][Full Text] [Related]
19. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
20. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
